Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Methoxyetomidate

Add links
From Wikipedia, the free encyclopedia

Methoxyetomidate
Clinical data
Other namesET-26; Moxetomidate
Identifiers
  • 2-methoxyethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H18N2O3
Molar mass274.320 g·mol−1
3D model (JSmol)
  • [C@H](C)(N1C(C(OCCOC)=O)=CN=C1)C2=CC=CC=C2
  • InChI=InChI=1S/C15H18N2O3/c1-12(13-6-4-3-5-7-13)17-11-16-10-14(17)15(18)20-9-8-19-2/h3-7,10-12H,8-9H2,1-2H3/t12-/m1/s1
  • Key:JJSJTELMIQBHDE-GFCCVEGCSA-N

Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1][2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3][1]

References

[edit]
  1. 1 2 "ET-26 Methoxyetomidate Hydrochloride Development Information". Synapse by Patsnap. Retrieved 2024-11-23.
  2. ↑ Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W (2017). "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE. 12 (8) e0183439. Bibcode:2017PLoSO..1283439W. doi:10.1371/journal.pone.0183439. PMC 5557577. PMID 28813523.
  3. ↑ "ET-26 Clinical Trials Overview". Synapse by Patsnap. Retrieved 2024-11-23.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Methoxyetomidate&oldid=1330594141"